Biotech Values

[jbog]

U.S. Launch Progress
• Received FDA approval August 3rd
• 2017 access tracking in-line with expectations,
predominately in public channels
• Nine weeks post launch, achieved ~15% TRx
share, surpassing Zepatier position
• 2018 public and commercial contract
discussions underway


OUS Launch Progress
• Received EU approval July 28th
• Received Japan approval September 27th
• Launched in Germany, Italy and UK; Spain and
Japan launch expected by year-end
• Strong uptake in Germany, with approximately
40% market share 10 weeks post launch

Shows the stronghold Gilead has in the U.S. It'll take time but looks like it'll get better.